These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 22862907)
1. Neutropenic enterocolitis after high-dose chemotherapy and autologous stem cell transplantation: incidence, risk factors, and outcome. Gil L; Poplawski D; Mol A; Nowicki A; Schneider A; Komarnicki M Transpl Infect Dis; 2013 Feb; 15(1):1-7. PubMed ID: 22862907 [TBL] [Abstract][Full Text] [Related]
2. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877 [TBL] [Abstract][Full Text] [Related]
3. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Seropian S; Nadkarni R; Jillella AP; Salloum E; Burtness B; Hu GL; Zelterman D; Cooper DL Bone Marrow Transplant; 1999 Mar; 23(6):599-605. PubMed ID: 10217191 [TBL] [Abstract][Full Text] [Related]
4. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience. Waśko-Grabowska A; Rzepecki P; Oborska S; Barzał J; Gawroński K; Młot B; Szczylik C Transplant Proc; 2011 Oct; 43(8):3111-3. PubMed ID: 21996239 [TBL] [Abstract][Full Text] [Related]
5. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma. Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862 [TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
7. [Neutropenic enterocolitis after autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma - a case report]. Matsuoka D; Manabe M; Okita J; Takakuwa T; Harada N; Aoyama Y; Kumura T; Ohta T; Furukawa Y; Mugitani A Gan To Kagaku Ryoho; 2014 Apr; 41(4):513-5. PubMed ID: 24743372 [TBL] [Abstract][Full Text] [Related]
8. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. McCann S; Schwenkglenks M; Bacon P; Einsele H; D'Addio A; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vorkurka S; Quinn B; Blijlevens N; Bone Marrow Transplant; 2009 Jan; 43(2):141-7. PubMed ID: 18776926 [TBL] [Abstract][Full Text] [Related]
9. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898 [TBL] [Abstract][Full Text] [Related]
10. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Gil L; Kozlowska-Skrzypczak M; Mol A; Poplawski D; Styczynski J; Komarnicki M Bone Marrow Transplant; 2009 Jan; 43(2):121-6. PubMed ID: 18794866 [TBL] [Abstract][Full Text] [Related]
11. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401 [TBL] [Abstract][Full Text] [Related]
12. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma. Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642 [TBL] [Abstract][Full Text] [Related]
13. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773 [TBL] [Abstract][Full Text] [Related]
14. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies. Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466 [TBL] [Abstract][Full Text] [Related]
15. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Sobecks RM; Le Beau MM; Anastasi J; Williams SF Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956 [TBL] [Abstract][Full Text] [Related]
16. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Gil L; Styczynski J; Komarnicki M Infection; 2007 Dec; 35(6):421-7. PubMed ID: 17926001 [TBL] [Abstract][Full Text] [Related]
17. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670 [TBL] [Abstract][Full Text] [Related]
18. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783 [TBL] [Abstract][Full Text] [Related]
19. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362 [TBL] [Abstract][Full Text] [Related]
20. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]